Biofrontera Inc. (BFRI) AI Stock Analysis

Biofrontera Inc. is a biopharmaceutical company focused on the commercialization of pharmaceutical products targeting dermatological conditions within the United States. Central to its offerings is Ameluz, a prescription drug utilized in conjunction with the RhodoLED lamp series for photodynamic therapy. This treatment is specifically designed for both lesion-directed and field-directed therapy of actinic keratosis, particularly on the face and scalp. Additionally, Biofrontera Inc. provides Xepi, a prescription cream tailored for treating impetigo, underscoring its commitment to addressing various dermatological needs. Founded in 1997 and headquartered in Woburn, Massachusetts, the company commercializes innovative therapeutic solutions in the dermatology sector.

Biofrontera increased revenue from $24.1M in FY2021 to $41.7M in FY2025, recording a 5-year revenue CAGR of 17.2%. Gross margin widened significantly to 78.7% in FY2025 from 50.1% in FY2024 and 47.1% in FY2021. Operating margins improved from -104.6% in FY2021 to -21.9% in FY2025, while net losses narrowed from -$37.7M to -$10.5M over the same period. For the trailing twelve months ending June 30, 2026, revenue stood at $46.2M with an operating margin of -4.4% and net income yielding an EPS of -$0.43. In the quarter ended June 30, 2026, quarterly revenue grew 32.9% year-over-year.

As of June 30, 2026, Biofrontera held $4.7M in cash and short-term investments against total debt of $7.5M, leaving net debt at $2.8M. Shareholders' equity was $6.0M on total assets of $24.1M. The company reported a current ratio of 1.18 and a debt-to-equity ratio of 1.26. Operating cash flow in FY2025 was -$13.4M, resulting in free cash flow of -$13.4M after capital expenditures of $2,000.

Biofrontera holds a market capitalization of $12.2M and an enterprise value of $20.2M. The stock trades at a price-to-sales multiple of 0.3x and an EV-to-revenue multiple of 0.4x, compared to the median price-to-sales ratio of 4.1x for US-listed Healthcare peers. Its forward P/E stands at 13.0x, below the US-listed Healthcare peer median of 17.3x. Over the past year, the stock fell 17.0%, underperforming the S&P 500 (SPY) gain of 16.8%, but gained 44.2% year-to-date through October 16, 2026.

Consensus coverage shows 2 Strong Buy ratings, 0 Buy, 0 Hold, and 0 Sell ratings. The mean price target is $6.00, representing a 629.9% premium to the October 16, 2026 closing price of $0.82. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $46.1M and an EPS of -$0.18. For the next fiscal year, projected EPS is $0.43 on revenue of $53.5M. The company has beat EPS estimates in 2 of the last 4 quarters, with the next earnings report scheduled for November 11, 2026.

This page is an AI-written research summary of Biofrontera Inc. (BFRI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BFRI income statement, BFRI balance sheet, BFRI key metrics, BFRI analyst forecast, BFRI chart. See the BFRI stock overview for the latest quote and news.